Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    RFP – Nonhuman Primate Virology Laboratory for AIDS Vaccine Research

    By Global Biodefense StaffFebruary 6, 2017
    HIV particles infecting a human H9 T-cell
    Share
    Facebook LinkedIn Reddit Email

    The National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals from organizations capable of conducting quantitative viral RNA measurements for assessment of HIV/SIV vaccine efficacy in preclinical studies with nonhuman primates.

    NIAID provides immunological and virological support for nonhuman primate studies conducted at NIAID’s Simian Vaccine Evaluation Unit (SVEU) contract sites and by AIDS vaccine researchers through three Nonhuman Primate Immunology and Virology Laboratories for AIDS Vaccine Research and Development, previously called the NHP “Core Laboratories.”

    The objective of the Core Laboratories has been to ensure standardization and comparability of the assays conducted for preclinical NHP studies and to provide a common basis for assessment of the immunogenicity and efficacy of candidate HIV and SIV vaccines.

    Advanced BioScience Laboratories, Inc. holds the current contract for the Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development (HHSN272201100022C).

    The purpose of the proposed contract is to provide a NHP virology laboratory that will conduct quantitative viral RNA measurements in support of studies that evaluate prototype AIDS vaccines in nonhuman primates.

    The contract will support the conduct, improvement, and development of assays designed to measure viral RNA loads in nonhuman primates that have been immunized with candidate HIV or SIV vaccines and challenged with SIV or SHIV in studies conducted at DAIDS Simian Vaccine Evaluation Unit contract sites or by NIH-supported investigators.

    It is anticipated that one cost reimbursement, term type contract will be awarded for a 1-year Base period plus six 1-year options for a possible total period of performance of 7 years beginning on or about December 29, 2017.

    Further details are available via Solicitation Number: NIAID-DAIDS-NIHAI2016075. The response deadline is February 15, 2017.

    HIV Request for Proposals Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – February 5, 2017
    Next Article New Method Enables Rapid testing of Nanoparticles for Countermeasure Delivery

    Related Stories

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    Call for Experts: Smallpox Medical Countermeasures

    October 28, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.